Influenza Clinical Trial
Official title:
A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Intravenous Peramivir in Healthy Subjects
This study will evaluate the safety and tolerability of peramivir, a new drug to treat
influenza. The study will administer gradually increasing doses of the drug in successive
small groups of subjects to determine the optimal dose that is safe and well tolerated. It
will be studied first at a single dose and then in multiple doses. The study will also
determine how long peramivir stays in the body and how high the drug levels are in the blood.
Men and women 18 - 40 years of age who weigh at least 110 lbs. and have a body mass index
(BMI) between 19 and 32 may be eligible for this study. Candidates are screened with a
medical history, physical examination, electrocardiogram (EKG), and blood and urine tests.
Part I - Single Dose Escalation
Participants are admitted to the NIH hospital for 32 to 40 hours for a single 15-minute
intravenous infusion of peramivir or placebo (saline), followed by monitoring and evaluation.
The drug dose is increased in successive groups of eight subjects; in each group, six
subjects are given peramivir and two receive placebo. The first group receives 0.5 mg/kg of
peramivir; subsequent groups receive increasingly higher doses (1, 2, 3.5, and 5 mg/kg) as
long as the last dose was well tolerated by the preceding group. Blood samples are drawn and
subjects are monitored for vital signs (temperature, blood pressure and heart rate) and for
symptoms such as headache, nausea, shortness of breath or pain at 0.5, 1, 2, 3, 6, 9, 12, 18
and 24 hours after the drug infusion. At the 24-hour evaluation they have an EKG. If needed,
an echocardiogram (ultrasound examination of the heart) may also be done. Subjects return to
the clinic 2, 3, 7, 14, and 28 days after the infusion for a check of vital signs, review of
symptoms, blood draw, and urine sample collection. In addition, subjects are asked to collect
all their urine for the first 48 hours after the study drug infusion.
Part II - Multi-dose Escalation
Groups of 16 subjects receive an intravenous infusion of peramivir (12 subject) or placebo (4
subjects) once a day for 5 consecutive days. The first four infusions are given in the NIH
outpatient clinic. The dose of peramivir is increased in successive groups of 16 subjects as
long as the preceding dose was well tolerated. Before the infusion on day 1, subjects have a
physical examination, blood test and EKG to obtain baseline values. After the infusion, they
remain in the hospital for 6 hours. Vital signs and symptoms are c...
Human influenza is a serious disease causing over 30,000 deaths in the United States each
year, and avian influenza presents a threat of a future pandemic. Despite this burden of
current and potential disease, there are no parenteral treatments for influenza, and
currently, the most common treatment (oseltamivir) is expensive and complex to manufacture.
The primary purpose of this protocol is to evaluate the safety and tolerability of
intravenous peramivir, a neuraminidase inhibitor. Beginning with a low single-dose, the
safety and tolerability is established by evaluating symptoms, clinical laboratory tests,
ECG, and pharmacokinetics. Utilizing a series of stopping rules and a medical monitor, the
dose will be escalated as safety and tolerability are established. Once the maximum tolerated
dose (MTD) is established in the first part of this trial (either limited by adverse effects
or up to maximum anticipated dose), the safety and tolerability of multi-dose administration
will begin (replicating anticipated clinical use). These cohorts will be evaluated using
similar criteria. The dose used in the multi-dose cohorts will also be escalated as safety
and tolerability are established.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |